Reuters: IPOX® Analyst Muehlbauer Discusses Wealthfront's IPO and Fintech Market Selectivity
IPOX® Research Analyst Lukas Muehlbauer was featured in Reuters discussing Wealthfront’s $2.63 billion Nasdaq debut. While the fintech raised $484.6 million, its flat opening highlighted ongoing market caution. Muehlbauer noted that "investors are still selective," distinguishing between high-profile wins and mixed broader performance. His commentary underscores the critical nuance required when analyzing shifting sentiment within the recovering fintech IPO landscape.
Reuters: IPOX® CEO Josef Schuster Comments on Lumexa Imaging's IPO and Market Trends
In a recent Reuters article, IPOX® CEO Josef Schuster analyzes the successful $462.5 million IPO of Lumexa Imaging amidst the year-end market rush. Schuster highlights that while investor appetite exists for the "right deal," there is notable caution regarding sectors with poor post-IPO returns, such as Silicon Valley-backed crypto and AI ventures. Read more about his insights on the current selective IPO landscape.
Reuters & Equipment Finance News: IPOX® Analyst Muehlbauer Comments on EquipmentShare.com IPO Filing
Construction tech firm EquipmentShare revealed significant revenue growth in its recent US IPO paperwork. IPOX® Research Analyst Lukas Muehlbauer provided key insights on the filing, noting the company’s sensitivity to interest rates due to capital deployment for its rental fleet. Muehlbauer also discussed the broader market trend, suggesting companies are rushing filings to avoid potential volatility and uncertainty surrounding Federal Reserve leadership changes in 2026.
Reuters: IPOX® CEO Schuster Comments on Medline's 'Blockbuster' $55 Billion IPO Target
In a recent Reuters article, IPOX® CEO Josef Schuster analyzes Medline’s targeted $55 billion listing, poised to be 2025’s largest IPO. Dr. Schuster highlights the deal as a critical test for market breadth beyond tech, describing the company as an "amazing American growth story." His commentary underscores the vital role of public markets in funding expansion as Medline seeks to raise over $5 billion in this blockbuster offering.
Reuters: IPOX® Analyst Muehlbauer comments on Andersen's $1.75 Billion IPO
IPOX® Analyst Lukas Muehlbauer comments on Andersen Group's $1.75 billion IPO in a recent Reuters article. Muehlbauer describes the listing as a "resurrection story" for the brand formerly linked to Arthur Andersen. He notes that the decision to list now suggests management is prioritizing immediate capital access over 2026 volatility, while strategically aligning the deal with strong financial results from tax-extension seasonality.
Bloomberg: IPOX® Founder Josef Schuster comments on Canada's Shrinking Stock Market and IPO Outlook
A recent Bloomberg article examines the contraction of Canada’s public markets, where delistings are outpacing IPOs. IPOX® CEO Josef Schuster weighs in on the lack of domestic momentum, noting that Canadian firms are growing but often listing elsewhere. He emphasizes the need for a "strong first deal" to act as a catalyst and reignite the Canadian IPO market for the coming year.
The IPOX® Update 12/06/2025
AI takes the lead as Anthropic preps for a potential 2026 IPO and Baidu’s Kunlunxin eyes a Hong Kong listing. IPOX® Associate Lukas Muehlbauer comments on Wealthfront’s $2.05 billion target amid mixed sentiment. Elsewhere, Unilever’s ice cream unit advances spin-off plans, Barrick Gold explores a North American IPO, and Morgan Stanley predicts a dealmaking surge, even as travel unicorn Klook delays its U.S. debut.
Kiplinger Features IPOX® 100 U.S. Index and FPX ETF as Strategy for Navigating 2025 IPO Market
In Kiplinger, David Milstead examines the surging U.S. IPO market, cautioning against risks from heavy AI and cryptocurrency concentration. He suggests navigating this volatility through diversified ETFs rather than individual stocks. Milstead highlights the First Trust US Equity Opportunities ETF (FPX), which tracks the IPOX® 100 U.S. Index. Up 39.3% in 2025, FPX captures major recent listings, offering investors broad exposure with reduced volatility compared to potentially riskier alternatives in this heated market.
Reuters: IPOX® Associate Muehlbauer Comments on Wealthfront’s $2.05 Billion IPO Target
Wealthfront targets a $2.05 billion valuation in its upcoming U.S. IPO. In recent Reuters coverage, IPOX® Associate Lukas Muehlbauer discusses the firm's strategic positioning at the "intersection of artificial intelligence and fintech." Muehlbauer highlights that while investor demand for new listings remains high, market sentiment is still susceptible to volatility. Read the full post for insights on Wealthfront’s plans and the current IPO market landscape.
The IPOX® Update 11/29/2025
Bill Ackman targets a massive $5 billion IPO for a new closed-end fund, while sports tech firm Enhanced agrees to a $1.2 billion SPAC merger. IPOX® CEO Josef Schuster notes the SPAC model’s enduring relevance following the deal. Elsewhere, the UK introduces stamp duty relief to revitalize London listings, and Hong Kong sees a flurry of activity with Syngenta’s potential pivot and new filings from Suzhou Novosense and Muyuan Foods.
Reuters: IPOX® CEO Schuster Comments on Enhanced’s $1.2 Billion SPAC Deal
Sports technology firm Enhanced plans to go public via a $1.2 billion merger with A Paradise Acquisition Corp, highlighting a resurgence in the blank-check market. IPOX CEO Josef Schuster noted that "SPACs are here to stay," driven by the success of innovative companies from the previous cycle. Co-founded by Christian Angermayer, the company plans to host sporting events where performance-enhancing drugs are allowed. The company expects to list on the Nasdaq under the ticker "ENHA" in the first half of 2026.
Bloomberg: IPOX® Founder Josef Schuster Discusses Crypto Sector Challenges in the IPO Market
In a new Bloomberg feature, IPOX® Schuster Founder Josef Schuster discusses the impact of the recent crypto crash on the US IPO market. With returns from new listings waning, Schuster notes that crypto is currently the "least favored sector" due to sustained investor losses. He suggests that while upcoming issuers may not need to postpone their debuts, they will likely face pressure to adjust pricing expectations downward. Read more about the challenging landscape for digital asset public offerings.
The IPOX® Update 11/22/2025
Asia-Pacific dominates this week, led by SBI Shinsei Bank’s potential $2.4 billion Tokyo relisting and CK Hutchison’s plan for a $2 billion AS Watson float. Singapore sees UltraGreen.ai targeting $400 million, while the U.S. pipeline heats up with crypto giant Kraken filing for a 2026 debut and Grayscale seeking a NYSE spot. MENA activity is strong with Saudi Global Ports eyeing $1 billion. Meanwhile, Uzbekistan’s sovereign fund prepares for a historic London listing, signaling renewed global momentum across diverse sectors.
Reuters: IPOX® CEO Josef Schuster Comments on Central Bancompany's Nasdaq Debut
On November 20, Central Bancompany shares climbed in their Nasdaq debut, securing a $5.26 billion valuation after raising $373 million. The listing continues a strong year for financial IPOs. IPOX® CEO Josef Schuster commented on investor confidence, stating, “The bank's successful trajectory fits well with investors looking for exposure to banks operating in markets with strong economic growth.” The Missouri-based lender manages $19.2 billion in assets.